1
|
Finlay HJ, Lloyd J, Vaccaro W, Kover A, Yan L, Bhave G, Prol J, Huynh T, Bhandaru R, Caringal Y, DiMarco J, Gan J, Harper T, Huang C, Conder ML, Sun H, Levesque P, Blanar M, Atwal K, Wexler R. Correction to Discovery of (( S)-5-(Methoxymethyl)-7-(1-methyl-1 H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5- a]pyrimidin-6-yl)(( S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective I Kur Inhibitor. J Med Chem 2013. [DOI: 10.1021/jm4010576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Finlay HJ, Lloyd J, Vaccaro W, Kover A, Yan L, Bhave G, Prol J, Huynh T, Bhandaru R, Caringal Y, DiMarco J, Gan J, Harper T, Huang C, Conder ML, Sun H, Levesque P, Blanar M, Atwal K, Wexler R. Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective IKur Inhibitor. J Med Chem 2012; 55:3036-48. [DOI: 10.1021/jm201386u] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Heather J. Finlay
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - John Lloyd
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Wayne Vaccaro
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Alexander Kover
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Lin Yan
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Gauri Bhave
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Joseph Prol
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Tram Huynh
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Rao Bhandaru
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Yolanda Caringal
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - John DiMarco
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Jinping Gan
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Tim Harper
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Christine Huang
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Mary Lee Conder
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Huabin Sun
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Paul Levesque
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Michael Blanar
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Karnail Atwal
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| | - Ruth Wexler
- Departments of Discovery Chemistry, ‡Crystallography, §Biology and ∥Preclinical Candidate
Optimization, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey
08543-5400, United States
| |
Collapse
|
4
|
Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava RA. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist. J Pharmacol Exp Ther 2008; 327:716-26. [PMID: 18799592 DOI: 10.1124/jpet.108.143271] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The first generation peroxisome proliferator-activated receptor (PPAR) alpha agonist gemfibrozil reduces the risk of major cardiovascular events; therefore, more potent PPARalpha agonists for the treatment of cardiovascular diseases have been actively sought. We describe two novel, potent oxybenzylglycine PPARalpha-selective agonists, BMS-687453 [N-[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]-N-(methoxycarbonyl)-glycine] and BMS-711939 N-[[5-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-fluorophenyl]methyl]-N-(methoxycarbonyl)-glycine], that robustly increase apolipoprotein (Apo) A1 and high-density lipoprotein cholesterol in human ApoA1 transgenic mice and lower low-density lipoprotein-cholesterol and triglycerides in fat-fed hamsters. These compounds have much lower potency against mouse PPARalpha than human PPARalpha; therefore, they were tested in PPARalpha-humanized mice that do not express murine PPARalpha but express human PPARalpha selectively in the liver. We developed hepatic gene induction as a novel biomarker for efficacy and demonstrate hepatic gene induction at very low doses of these compounds. BMS-711939 induces fecal cholesterol excretion, which is further increased upon cotreatment with a liver X receptor (LXR) agonist. It is surprising that this synergistic increase upon coadministration is also observed in mice that express PPARalpha in the liver only. BMS-711939 also prevented the LXR agonist-induced elevation of serum triglycerides. Such PPARalpha agonists could be attractive candidates to explore for the treatment of cardiovascular diseases, especially in combination with a suitable LXR agonist.
Collapse
Affiliation(s)
- Ranjan Mukherjee
- Department of Atherosclerosis, Bristol-Myers Squibb Company, Research and Development, Pennington, NJ 08534, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|